Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surufatinib plus toripalimab for recurrent ovarian clear cell carcinoma
ChiCTR2400083672Phase 2Recruiting
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- Apr 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of surufatinib and toripalimab in clear cell ovarian cancer, sponsored by Fudan University Shanghai Cancer Center. Primary endpoint: Progression-free survival. Started Apr 2024; status: recruiting.
02
Drugs
surufatinibtoripalimab
03
Conditions
clear cell ovarian cancer
Beyond the preview
Go deeper on ChiCTR2400083672.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400083672.